Literature DB >> 10907390

Nonalcoholic steatohepatitis.

K S Kumar1, P F Malet.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a liver disease that, until recently, has been underrecognized as a common cause of elevated liver enzymes. This distinct clinical entity is characterized by liver biopsy findings similar to those seen in alcoholic hepatitis but in the absence of alcohol consumption sufficient to cause such changes. Patients with NASH are often middle-aged and obese, with coexisting diabetes or hyperlipidemia, but NASH also occurs in younger lean, otherwise healthy individuals and even in children. Although NASH is generally a benign disorder, it may be progressive, leading to cirrhosis and complications of portal hypertension. Liver biopsy remains the gold standard for diagnosis. Therapy for NASH remains poorly defined, although weight reduction and ursodeoxycholic acid may have a beneficial effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10907390     DOI: 10.4065/75.7.733

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  10 in total

1.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey.

Authors:  Lei Shen; Jian-Gao Fan; Yan Shao; Min-De Zeng; Jun-Rong Wang; Guo-Hao Luo; Ji-Qiang Li; Si-Yao Chen
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

2.  Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program.

Authors:  Cary H Patt; Hwan Y Yoo; Kourosh Dibadj; John Flynn; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

3.  Methionine deficiency and hepatic injury in a dietary steatohepatitis model.

Authors:  Helieh S Oz; Theresa S Chen; Manuela Neuman
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

4.  A case-control study of non-alcoholic fatty liver disease in breast cancer.

Authors:  Ahmet Bilici; Mustafa Ozguroglu; Ismail Mihmanli; Hande Turna; Ibrahim Adaletli
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

5.  Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?

Authors:  C D J Evans; K A Oien; R N M MacSween; P R Mills
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

6.  Long term highly saturated fat diet does not induce NASH in Wistar rats.

Authors:  Caroline Romestaing; Marie-Astrid Piquet; Elodie Bedu; Vincent Rouleau; Marianne Dautresme; Isabelle Hourmand-Ollivier; Céline Filippi; Claude Duchamp; Brigitte Sibille
Journal:  Nutr Metab (Lond)       Date:  2007-02-21       Impact factor: 4.169

7.  Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis.

Authors:  Mei Yang; Dongping Xu; Yuan Liu; Xiaodong Guo; Wenshu Li; Chaonan Guo; Hongping Zhang; Yinjie Gao; Yuanli Mao; Jingmin Zhao
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

8.  Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation of the liver X receptor in mice.

Authors:  Aldo Grefhorst; Elizabeth J Parks
Journal:  J Lipid Res       Date:  2009-03-14       Impact factor: 5.922

9.  Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients.

Authors:  Hossein Bahrami; Nasser Ebrahimi Daryani; Shahram Mirmomen; Farin Kamangar; Babak Haghpanah; Mehdi Djalili
Journal:  BMC Gastroenterol       Date:  2003-10-16       Impact factor: 3.067

10.  Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis.

Authors:  Tracey Hurrell; Vlasia Kastrinou-Lampou; Achilleas Fardellas; Delilah F G Hendriks; Åsa Nordling; Inger Johansson; Audrey Baze; Céline Parmentier; Lysiane Richert; Magnus Ingelman-Sundberg
Journal:  Cells       Date:  2020-04-14       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.